Features of treatment of focal epilepsia in adults

main manifestation of which are epileptic seizures. Advances in the treatment of epilepsy are achieved by improving the diagnosis of various forms of the disease and individualization of therapy. Focal epilepsy, the clinical core of which is focal seizures, including those with impaired con sciousness and secondary generalization, is the most common form of the disease in adults up to 6070% of cases, about half of which have tempo ral epilepsy [1]. There is a symptomatic focal epilepsy caused by brain damage of a known organ ic nature, and presumably symptomatic (crypto genic). Diagnosis of focal epilepsy includes the fol lowing stages, allowing to verify the diagnosis and assess the patient's health [2]: 1) the study of the seizure seizures; 2) anamnesis collection; 3) study of neurological and somatic status; 4) neuropsychological testing (assessment of the cognitive and emotionalemotional sphere); 5) electroencephalographic studies, including video electroencephalography; 6) neuroimaging (magnetic resonance imaging of the brain, including with the use of regimes that allow to optimize the diagnosis of hippocampal lesions and heterotopia of gray matter); 7) laboratory studies (clinical and biochemical analysis of blood, ultrasound examination of inter nal organs). Only after confirming the epileptic nature of seizures and diagnosing epilepsy does the doctor determine the tactics of the patient's management. The goal of epilepsy treatment is to save the patient from attacks and improve the quality of life. In patients with rare seizures (less than 1 per year), one can refrain from prescribing antiepileptic drugs (PAD) [3], explaining to the patient the importance of compliance with sleep and rest, refusal of alco hol. In some cases, when an epileptogenic focal brain lesion is detected (according to the methods of neuroimaging), treatment begins after the first attack. According to international and Russian rec ommendations, treatment for the first time diag nosed epilepsy begins in the monotherapy regime. In Uzbekistan, as the monotherapy of the first line in focal epilepsy, the following PADs were record ed: basic (carbamazepine, valproate), a new gener ation of PAD (lamotrigine, oxcarbazepine, topira mate, levetiracetam, gabapentin). Pregabalin, lacosamide is registered in our country as an addi tional therapy. “The old” PAD (barbiturates, diphe nine) are not drugs of the first order of choice. Antiepileptic drugs of the new generation differ from the basic and “old” drugs with better tolerabil ity [2,4,5]. The choice of PET should be based on data on efficacy, tolerability, side effects, pharma cokinetics, pharmacodynamics, mechanisms of action, interdrug interactions, the rate of titration (the speed of reaching the required doses) of the PET, as well as patient data (age, sex, comorbid pathology). As a rule, PAD is prescribed in minimal FEATURES OF TREATMENT OF FOCAL EPILEPSIA IN ADULTS